Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654286 | 0.82 | L3MBTL1 (0.52) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL6599392 | 0.80 | SMN1; SMN2 (0.50) | L3MBTL1HSD17B10SMN1; SMN2POLBGAA | |
| SCHEMBL7191670 | 0.78 | SMN1; SMN2 (0.39) | L3MBTL1TSHRSMN1; SMN2POLBRAB9A | |
| SCHEMBL21300279 | 0.77 | L3MBTL1 (0.47) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL21300507 | 0.76 | L3MBTL1 (0.46) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL3753324 | 0.75 | L3MBTL1 (0.64) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| Sulfuric Acid SCHEMBL30521499 | 0.73 | GLA (0.55) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL13522679 | 0.73 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2262931 | 0.73 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL423999 | 0.73 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | claimed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | L3MBTL1 4783/4885TSHR 4411/4885ALOX15 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.